Literature DB >> 32372168

Validation of Three European Risk Scores to Predict Long-Term Outcomes for Patients Receiving Cardiac Resynchronization Therapy in an Asian Population.

Shengwen Yang1, Zhimin Liu1, Wenran Li2, Yiran Hu1, Shangyu Liu1, Ran Jing1, Wei Hua3,4.   

Abstract

To validate externally and recalibrate three European risk scores for all-cause mortality and transplantation in patients receiving cardiac resynchronization therapy (CRT) in an Asian population. Data were collected at our institution between January 2010 and December 2017. The primary endpoints were all-cause mortality and heart transplantation. Of the 506 patients who were followed for 2 years, 104 reached the primary endpoint. The Kaplan-Meier event-free survival analysis, stratified according to the three scores, yielded significant results (log-rank test, all P < 0.05), with a good fit between the predicted and observed event rates (Hosmer-Lemeshow goodness-of-fit test, all P > 0.05). The ScREEN score yielded the best discriminatory power for the primary endpoints compared with the VALID-CRT and EAARN scores. ScREEN was the best predictor of all-cause mortality and heart transplantation. Risk scores based on different populations should be selected cautiously. Graphical Abstract.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiac resynchronization therapy; Risk score model; Validation

Mesh:

Year:  2020        PMID: 32372168     DOI: 10.1007/s12265-020-09999-y

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  24 in total

1.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

2.  Cardiac-resynchronization therapy for mild-to-moderate heart failure.

Authors:  Anthony S L Tang; George A Wells; Mario Talajic; Malcolm O Arnold; Robert Sheldon; Stuart Connolly; Stefan H Hohnloser; Graham Nichol; David H Birnie; John L Sapp; Raymond Yee; Jeffrey S Healey; Jean L Rouleau
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients.

Authors:  Kenneth C Bilchick; Sandeep Kamath; John P DiMarco; George J Stukenborg
Journal:  Circulation       Date:  2010-11-01       Impact factor: 29.690

4.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

Review 5.  Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review.

Authors:  Finlay A McAlister; Justin Ezekowitz; Nicola Hooton; Ben Vandermeer; Carol Spooner; Donna M Dryden; Richard L Page; Mark A Hlatky; Brian H Rowe
Journal:  JAMA       Date:  2007-06-13       Impact factor: 56.272

6.  Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms.

Authors:  Cecilia Linde; William T Abraham; Michael R Gold; Martin St John Sutton; Stefano Ghio; Claude Daubert
Journal:  J Am Coll Cardiol       Date:  2008-11-07       Impact factor: 24.094

7.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Authors:  Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2014-02-05       Impact factor: 24.094

8.  QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy.

Authors:  Pamela N Peterson; Melissa A Greiner; Laura G Qualls; Sana M Al-Khatib; Jeptha P Curtis; Gregg C Fonarow; Stephen C Hammill; Paul A Heidenreich; Bradley G Hammill; Jonathan P Piccini; Adrian F Hernandez; Lesley H Curtis; Frederick A Masoudi
Journal:  JAMA       Date:  2013-08-14       Impact factor: 56.272

9.  Cardiac-resynchronization therapy for the prevention of heart-failure events.

Authors:  Arthur J Moss; W Jackson Hall; David S Cannom; Helmut Klein; Mary W Brown; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Steven L Higgins; Marc A Pfeffer; Scott D Solomon; David Wilber; Wojciech Zareba
Journal:  N Engl J Med       Date:  2009-09-01       Impact factor: 91.245

10.  EAARN score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on pre-implantation risk factors.

Authors:  Malek Khatib; José M Tolosana; Emilce Trucco; Roger Borràs; Angeles Castel; Antonio Berruezo; Adelina Doltra; Marta Sitges; Elena Arbelo; Maria Matas; Josep Brugada; Lluís Mont
Journal:  Eur J Heart Fail       Date:  2014-05-23       Impact factor: 15.534

View more
  1 in total

1.  Lead one ratio: A new electrocardiogram marker for cardiac resynchronization therapy response.

Authors:  Ajay Raj; Ranjit Kumar Nath; Bhagya Narayan Pandit; Ajay Pratap Singh; Neeraj Pandit; Puneet Aggarwal
Journal:  ARYA Atheroscler       Date:  2021-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.